$NTHIOct 14, 2026, 10:18 AM ETAI processed
NTHI adds Abu Dhabi banking exec to board as Abu Dhabi DoH clears IND path for NEO212
AI Summary
NeOnc (NTHI) appointed Ali Alabedin, a senior Abu Dhabi banking executive, to its board to bolster international finance/governance expertise as the company expands its regional footprint. The Department of Health – Abu Dhabi granted investigational new drug authorization supporting NEO212 development in the UAE (subject to ethics approvals), and NeOnc also highlighted positive topline NEO100 Phase 2a data (24 patients: 6‑month PFS 48.9% vs 20% benchmark; median OS 26.09 months). The company has an End-of-Phase 1 Type B meeting with the FDA on Nov 17 to discuss NEO212 Phase 2 design and regulatory pathway.
Positives
- Appointed Ali Alabedin, bringing 30+ years of international banking and governance experience and Abu Dhabi connections
- Abu Dhabi DoH granted IND authorization supporting NEO212 development in UAE, opening a regional clinical path (pending ethics approvals)
- Reported positive topline NEO100 Phase 2a results in 24 patients (6‑month PFS 48.9% vs 20% prespecified benchmark; median OS 26.09 months)
Negatives
- Abu Dhabi IND authorization is conditional (requires ethics approvals) and does not indicate marketing approval or confirmed patient enrollment
- NEO100 Phase 2a results are from a small 24‑patient cohort, so findings are preliminary
- Regulatory path still uncertain — Phase 2 design and approvals depend on upcoming FDA feedback (Nov 17 End-of-Phase 1 meeting)